Retatrutide, a triple-agonist weight loss drug still in clinical trials, is being sold online without FDA approval. While early results suggest it could surpass current GLP-1 drugs in effectiveness, ...

Retatrutide shows big weight loss potential but isn’t FDA-approved. Here’s what to know about its safety and legal risks.

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.

Are you thinking about starting a GLP-1 medication? About 1 in 8 US adults have used GLP-1s to manage diabetes, treat heart disease, or lose weight.  “At this time, there is no other medication like ...

SAN DIEGO -- An investigational triple-hormone receptor agonist yielded major weight loss in people with obesity, a phase II trial showed. By 24 weeks, patients on any of the four doses of once-weekly ...

Novo Nordisk (CPSE:NOVO B) and United Laboratories report phase 2 data from China for UBT251 in type 2 diabetes. UBT251, a triple agonist, shows greater reductions in HbA1c and body weight than ...

Rachael Link is a registered dietitian and health writer based in San Francisco. She completed her undergraduate degree at the University of Central Missouri and holds a master’s degree from New York ...

Mestag Therapeutics, a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory disease, announced today that it has been selected to ...